Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer

Seminars in Thoracic and Cardiovascular Surgery

Volumn 20, Issue 3, 2008, Pages 204-209

  Price, Katharine A R ^a   Azzoli, Christopher G ^a   Gaspar, Laurie E ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

chemoradiation; non small cell lung cancer; treatment

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CORTICOSTEROID; DOCETAXEL; ETOPOSIDE; FOLIC ACID ANTAGONIST; GEFITINIB; GEMCITABINE; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; VINBLASTINE; VINDESINE;

ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS DISEASE; ESOPHAGUS TOXICITY; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; HEARING LOSS; HUMAN; INFECTION; KIDNEY INJURY; LEUKOPENIA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NERVE INJURY; NEUTROPENIA; OTOTOXICITY; OVERALL SURVIVAL; RADIATION DOSE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PNEUMONECTOMY; RADIOTHERAPY, ADJUVANT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 56349103686     PISSN: 10430679     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2008.09.007     Document Type: Article

References (16)

1. Govindan R., Bogart J., Wang X., et al. A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407-early evaluation of feasibility and toxicity. J Clin Oncol (2008) 26 (May 20 suppl) (abstract 7518)
2. Dillman R.O., Herndon J., Seagren S.L., et al. Improved survival in stage III non-small cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88 (1996) 1210-1215
3. Sause W., Kolesar P., Taylor S., et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117 (2000) 358-364
4. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
5. Curran W.J., Scott C.B., Langer C.J., et al. Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III NSCLC: RTOG 9410. J Clin Oncol (2003) 22 (abstract 2499)
6. Zatloukal P., Petruzelka L., Zemanova M., et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46 (2004) 87-98
7. Fournel P., Robinet G., Thomas P., et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. J Clin Oncol 23 (2005) 5910-5917
8. Auperin A., Rolland E., Curran W., et al. Concomitant radio-chemotherapy (RT-CT) versus sequential RT-CT in locally advanced non-small cell lung cancer (NSCLC): A meta-analysis using individual patient data (IPD) from randomized clinical trials (RCTs). J Thoracic Onc 2 (2007) S310
9. Vokes E.E., Herndon J.E., Kelley M.J., et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25 (2007) 1698-1704
10. Gandara D.R., Chansky K., Albain K.S., et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 21 (2003) 2004-2010
11. Hanna N.H., Neubauer M., Ansari R., et al. Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023. J Clin Oncol 25 (2007) 7512
12. Belani C.P., Choy H., Bonomi P., et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23 (2005) 5883-5891
13. Kelly K., Chansky K., Gaspar L.E., et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small cell lung cancer: SWOG S0023. J Clin Oncol 26 (2008) 2450-2456
14. Langer C.J., Wakelee H., Schiller J., et al. Cooperative group portfolio in locally advanced non-small cell lung cancer: are we making progress?. Clin Lung Cancer 9 (2008) 85-91
15. Blumenschein G.R., Paulus R., Curran W.J., et al. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): A report of the 2 year and median survival (MS) for the RTOG 0324 trial. J Clin Oncol (2008) 26 (May 20 suppl) (abstract 7516)
16. Gridelli C., Langer C., Maione P., et al. Lung cancer in the elderly. J Clin Oncol 25 (2007) 1898-1907